|Bid||249.210 x 100|
|Ask||249.290 x 100|
|Day's Range||247.230 - 249.880|
|52 Week Range||184.500 - 261.270|
|PE Ratio (TTM)||7.75|
|Dividend & Yield||2.80 (1.14%)|
|1y Target Est||N/A|
One of the activist investor's greatest deals is under legal attack. There's no easy way out.
Doug Kass shares his thoughts on his Allergan profit and discussing adding Dillard's to his list.
Why are shares of Valeant Pharmaceuticals International (VRX) rising and does the market have it right? According to Evercore ISI analyst Umer Raffat, anytime the market receives a signal of some sort that the embattled drug maker has value beyond its pile of debt, the stock price rises and short sellers cover their positions. Today, a 7.8% spike in Valeant’s share price is linked to speculation that a debt-to-equity swap could be on the horizon, Raffat says.